Akari Therapeutics will present an overview of its ADC platform and 2026 milestones on January 13, 2026.
Quiver AI Summary
Akari Therapeutics, an oncology biotechnology company focused on developing antibody drug conjugates (ADCs) with innovative payloads, announced that CEO Abizer Gaslightwala will present at the 2026 Biotech Showcase in San Francisco on January 13, 2026, at 9:30 AM PT. The presentation will cover Akari’s ADC platform, strategic goals, and milestones for 2026. The company’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells, using the novel PH1 payload to induce cancer cell death and activate the immune system while minimizing off-target effects. Preclinical studies have shown promising results, and the company is preparing for First-In-Human trials by late 2026 or early 2027, in addition to advancing another candidate, AKTX-102, targeted at gastrointestinal and lung cancers.
Potential Positives
- Akari Therapeutics will showcase its innovative antibody drug conjugate (ADC) platform and lead candidate AKTX-101 at a prominent industry event, which could attract investor interest and enhance visibility.
- The company is utilizing a novel payload, PH1, which targets RNA splicing, differentiating itself from traditional ADCs and potentially offering a more effective cancer treatment.
- Preclinical studies indicate that AKTX-101 may induce cancer cell death and activate immune responses, suggesting robust therapeutic potential and improved outcomes over existing therapies.
- Plans for initiating First-In-Human trials for AKTX-101 by late 2026 or early 2027 demonstrate progress in the development pipeline, which could lead to future clinical advancements and funding opportunities.
Potential Negatives
- The press release highlights the company's timeline to start its First-In-Human trial for the lead candidate AKTX-101 by late 2026/early 2027, which may indicate significant delays in their drug development process.
- There is no mention of recent successes or advancements leading to the presentation, which could raise concerns about the current state of their pipeline and overall progress.
- The focus on one candidate (AKTX-101) and the lack of detailed results from preclinical studies may suggest a dependency on a single asset, potentially posing a risk to investor confidence if that asset underperforms.
FAQ
When is Akari's presentation at the 2026 Biotech Showcase?
Akari's presentation is scheduled for Tuesday, January 13, 2026, at 9:30 AM PST.
Where will the presentation take place?
The presentation will be held in Yosemite A at the Ballroom Level in San Francisco, CA.
Who will be presenting for Akari Therapeutics?
Abizer Gaslightwala, the President and CEO of Akari Therapeutics, will be presenting.
What is Akari's lead product candidate?
Akari's lead candidate is AKTX-101, which targets the Trop2 receptor on cancer cells.
What is the unique feature of Akari's ADC platform?
Akari's ADC platform utilizes a novel payload, PH1, which targets RNA splicing to modulate cancer cell behavior.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AKTX Insider Trading Activity
$AKTX insiders have traded $AKTX stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $AKTX stock by insiders over the last 6 months:
- ABIZER GASLIGHTWALA (CEO) has made 3 purchases buying 21,000 shares for an estimated $19,540 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$AKTX Hedge Fund Activity
We have seen 6 institutional investors add shares of $AKTX stock to their portfolio, and 5 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CRESSET ASSET MANAGEMENT, LLC added 804,060 shares (+4368.0%) to their portfolio in Q3 2025, for an estimated $812,100
- SABBY MANAGEMENT, LLC removed 179,785 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $181,582
- CWA ASSET MANAGEMENT GROUP, LLC added 55,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $15,894
- OMNIA FAMILY WEALTH, LLC removed 34,250 shares (-54.6%) from their portfolio in Q3 2025, for an estimated $34,592
- VIRTU FINANCIAL LLC added 22,502 shares (+inf%) to their portfolio in Q3 2025, for an estimated $22,727
- TWO SIGMA SECURITIES, LLC added 19,753 shares (+inf%) to their portfolio in Q3 2025, for an estimated $19,950
- RENAISSANCE TECHNOLOGIES LLC removed 17,415 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $17,589
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$AKTX Analyst Ratings
Wall Street analysts have issued reports on $AKTX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 09/09/2025
- Maxim Group issued a "Buy" rating on 07/18/2025
To track analyst ratings and price targets for $AKTX, check out Quiver Quantitative's $AKTX forecast page.
$AKTX Price Targets
Multiple analysts have issued price targets for $AKTX recently. We have seen 3 analysts offer price targets for $AKTX in the last 6 months, with a median target of $1.6.
Here are some recent targets:
- Aydin Huseynov from Ladenburg Thalmann set a target price of $1.0 on 01/05/2026
- Sean Lee from HC Wainwright & Co. set a target price of $1.6 on 09/09/2025
- Jason McCarthy from Maxim Group set a target price of $5.0 on 07/18/2025
Full Release
In-person presentation on Tuesday, January 13 th at 9:30 AM PT
As part of the presentation, Mr. Gaslightwala will provide an overview of Akari’s ADC platform, strategic priorities and key milestones for 2026
TAMPA, Fla. and LONDON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, today announced that Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics will present at the 2026 Biotech Showcase being held from January 12-14, 2026 in San Francisco, CA.
Presentation details are as follows:
Date/Time: Tuesday, January 13, 2026 at 9:30 AM PST
Location: Yosemite A (Ballroom Level)
In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website .
About Akari Therapeutics
Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune system to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGF3, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by late 2026/early 2027, and is also advancing AKTX-102, an ADC against a novel target highly relevant in GI and lung cancers.
For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn .
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
[email protected]
